Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Jeffrey S. Weber, Mario Mandalà et al.|Clinical Cancer Research|2023Cited by 185